Literature DB >> 15878202

An influx of macrophages is the predominant local immune response in ovine pulmonary adenocarcinoma.

C Summers1, M Norval, M De Las Heras, L Gonzalez, J M Sharp, G M Woods.   

Abstract

Infection with a retrovirus, Jaagsiekte sheep retrovirus (JSRV), causes ovine pulmonary adenocarcinoma (OPA). The excess production of surfactant proteins by alveolar tumour cells results in increased production of pulmonary fluid, which is characteristically expelled through the nostrils of affected sheep. The immune response to JSRV and the tumour is poorly understood: no JSRV-specific circulating antibodies or T cells have been detected to date. The aim of the present study was to obtain phenotypic evidence for a local immune response in OPA lungs. Specific-pathogen free lambs were infected intratracheally with JSRV. When clinical signs of OPA were apparent, the lungs were removed at necropsy and immunohistochemistry (IHC) was performed on lung sections using a panel of mouse anti-sheep mAbs. No influx of dendritic cells, B cells, CD4, CD8 or gammadelta T cells was seen in the neoplastic nodules or in their periphery. MHC Class II-positive cells were found intratumourally, peritumourally and in the surrounding alveolar lumina. In the tumours, many of these cells were shown to be fibroblasts and the remainder were likely to be mature macrophages. In the alveolar lumen, the MHC Class II-positive cells were CD14-positive and expressed high levels of IFN-gamma. They appeared to be immature monocytes or macrophages which then differentiated to become CD14-negative as they reached the periphery of the tumours. A high level of MHC Class I expression was detected on a range of cells in the OPA lungs but the tumour nodules themselves contained no MHC Class I-positive cells. On the basis of these findings, it is proposed that the lack of an effective immune response in OPA could result from a mechanism of peripheral tolerance in which the activity of the invading macrophages is suppressed by the local environment, possibly as a consequence of the inhibitory properties of the surfactant proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878202     DOI: 10.1016/j.vetimm.2005.03.006

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

1.  In vivo tumorigenesis by Jaagsiekte sheep retrovirus (JSRV) requires Y590 in Env TM, but not full-length orfX open reading frame.

Authors:  Chris Cousens; Naoyoshi Maeda; Claudio Murgia; Mark P Dagleish; Massimo Palmarini; Hung Fan
Journal:  Virology       Date:  2007-07-03       Impact factor: 3.616

2.  MHC class II DRB1 gene polymorphism in the pathogenesis of Maedi-Visna and pulmonary adenocarcinoma viral diseases in sheep.

Authors:  Amaia Larruskain; Esmeralda Minguijón; Koldo García-Etxebarria; Bernardino Moreno; Inmaculada Arostegui; Ramón A Juste; Begoña M Jugo
Journal:  Immunogenetics       Date:  2010-01-05       Impact factor: 2.846

Review 3.  Beyond tradition and convention: benefits of non-traditional model organisms in cancer research.

Authors:  Rebecca M Harman; Sanjna P Das; Arianna P Bartlett; Gat Rauner; Leanne R Donahue; Gerlinde R Van de Walle
Journal:  Cancer Metastasis Rev       Date:  2020-10-28       Impact factor: 9.264

4.  Exploiting ovine immunology to improve the relevance of biomedical models.

Authors:  Gary Entrican; Sean R Wattegedera; David J Griffiths
Journal:  Mol Immunol       Date:  2014-09-26       Impact factor: 4.407

5.  Clinical-histopathological and molecular study of ovine pulmonary adenocarcinoma in Awassi sheep in Al-Qadisiyah Province, Iraq.

Authors:  Khalefa Ali Mansour; Saad Hashim Al-Husseiny; Qassim Haleem Kshash; Asaad Jassim
Journal:  Vet World       Date:  2019-03-26

6.  Transcriptional Response of Ovine Lung to Infection with Jaagsiekte Sheep Retrovirus.

Authors:  Anna Eleonora Karagianni; Deepali Vasoya; Jeanie Finlayson; Henny M Martineau; Ann R Wood; Chris Cousens; Mark P Dagleish; Mick Watson; David J Griffiths
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.